Dr. Uqba Khan, M.D

NPI: 1780923920
Total Payments
$20,789
2024 Payments
$4,503
Companies
19
Transactions
47
Medicare Patients
937
Medicare Billing
$208,437

Payment Breakdown by Category

Consulting$19,588 (94.2%)
Food & Beverage$765.44 (3.7%)
Travel$340.28 (1.6%)
Education$96.25 (0.5%)
Other$0.00 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $19,588 12 94.2%
Food and Beverage $765.44 31 3.7%
Travel and Lodging $340.28 3 1.6%
Education $96.25 1 0.5%

Top Paying Companies

Company Total Records Latest Year
AstraZeneca Pharmaceuticals LP $9,834 13 $0 (2024)
BARD PERIPHERAL VASCULAR, INC. $7,311 4 $0 (2019)
Amgen Inc. $2,744 2 $0 (2023)
Incyte Corporation $335.00 1 $0 (2018)
Takeda Pharmaceuticals U.S.A., Inc. $129.10 3 $0 (2018)
E.R. Squibb & Sons, L.L.C. $63.77 4 $0 (2018)
Ipsen Biopharmaceuticals, Inc $59.58 3 $0 (2019)
Bayer HealthCare Pharmaceuticals Inc. $52.90 2 $0 (2022)
TESARO, Inc. $33.12 2 $0 (2018)
Celgene Corporation $31.71 2 $0 (2018)

Payment History by Year

Year Amount Transactions Top Company
2024 $4,503 8 AstraZeneca Pharmaceuticals LP ($4,503)
2023 $7,635 6 AstraZeneca Pharmaceuticals LP ($4,864)
2022 $516.58 4 AstraZeneca Pharmaceuticals LP ($467.48)
2020 $20.00 1 Lilly USA, LLC ($20.00)
2019 $7,375 7 BARD PERIPHERAL VASCULAR, INC. ($7,311)
2018 $664.69 16 Incyte Corporation ($335.00)
2017 $75.37 5 Pharmacyclics LLC, An AbbVie Company ($25.33)

All Payment Transactions

47 individual payment records from CMS Open Payments — Page 1 of 2

Date Company Product Nature Form Amount Type
10/23/2024 AstraZeneca Pharmaceuticals LP Consulting Fee Cash or cash equivalent $3,082.50 General
10/04/2024 AstraZeneca Pharmaceuticals LP IMFINZI (Biological) Travel and Lodging In-kind items and services $179.67 General
Category: Oncology
10/04/2024 AstraZeneca Pharmaceuticals LP IMFINZI (Biological) Food and Beverage In-kind items and services $78.14 General
Category: Oncology
10/04/2024 AstraZeneca Pharmaceuticals LP IMFINZI (Biological) Travel and Lodging Cash or cash equivalent $47.37 General
Category: Oncology
10/04/2024 AstraZeneca Pharmaceuticals LP IMFINZI (Biological) Food and Beverage Cash or cash equivalent $38.04 General
Category: Oncology
10/01/2024 AstraZeneca Pharmaceuticals LP IMFINZI (Biological) Consulting Fee Cash or cash equivalent $525.00 General
Category: Oncology
09/13/2024 AstraZeneca Pharmaceuticals LP IMFINZI (Biological) Food and Beverage In-kind items and services $27.70 General
Category: Oncology
05/22/2024 AstraZeneca Pharmaceuticals LP IMFINZI (Biological) Consulting Fee Cash or cash equivalent $525.00 General
Category: Oncology
12/10/2023 AstraZeneca Pharmaceuticals LP Consulting Fee Cash or cash equivalent $2,055.00 General
11/30/2023 ARRAY BIOPHARMA INC LORBRENA (Drug), BRAFTOVI, MEKTOVI Food and Beverage In-kind items and services $27.05 General
Category: ONCOLOGY
08/04/2023 AstraZeneca Pharmaceuticals LP IMJUDO (Biological) Consulting Fee Cash or cash equivalent $685.00 General
Category: Oncology
07/25/2023 AstraZeneca Pharmaceuticals LP IMJUDO (Biological) Consulting Fee Cash or cash equivalent $2,123.50 General
Category: Oncology
07/19/2023 Amgen Inc. LUMAKRAS (Drug) Consulting Fee Cash or cash equivalent $2,058.00 General
Category: Oncology
07/19/2023 Amgen Inc. LUMAKRAS (Drug) Consulting Fee Cash or cash equivalent $686.00 General
Category: Oncology
10/26/2022 Bayer HealthCare Pharmaceuticals Inc. Vitrakvi (Drug), Stivarga Food and Beverage In-kind items and services $33.40 General
Category: Oncology
07/03/2022 AstraZeneca Pharmaceuticals LP IMFINZI (Biological) Consulting Fee Cash or cash equivalent $342.50 General
Category: Oncology
06/04/2022 AstraZeneca Pharmaceuticals LP CALQUENCE (Drug) Food and Beverage In-kind items and services $124.98 General
Category: Oncology
04/26/2022 Sirtex Medical Inc SIR-Spheres Microspheres (Device) Food and Beverage Cash or cash equivalent $15.70 General
Category: Interventional Oncology
06/25/2020 Lilly USA, LLC VERZENIO (Drug) Food and Beverage In-kind items and services $20.00 General
Category: Oncology
09/10/2019 Bayer HealthCare Pharmaceuticals Inc. Stivarga (Drug) Food and Beverage In-kind items and services $19.50 General
Category: Oncology
07/12/2019 BARD PERIPHERAL VASCULAR, INC. LUTONIX (Device) Consulting Fee Cash or cash equivalent $3,850.00 General
Category: PERIPHERAL VASCULAR
07/12/2019 BARD PERIPHERAL VASCULAR, INC. LUTONIX (Device) Travel and Lodging Cash or cash equivalent $113.24 General
Category: PERIPHERAL VASCULAR
07/12/2019 BARD PERIPHERAL VASCULAR, INC. LUTONIX (Device) Food and Beverage In-kind items and services $27.50 General
Category: PERIPHERAL VASCULAR
06/13/2019 Bard Peripheral Vascular, Inc. Lutonix DCB (Device) Consulting Fee Cash or cash equivalent $3,320.00 General
Category: Peripheral Vascular
06/05/2019 Ipsen Biopharmaceuticals, Inc SOMATULINE DEPOT (Drug), ONIVYDE Food and Beverage In-kind items and services $20.50 General
Category: Oncology/Endocrinology

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 7 263 575 $223,745 $49,767
2022 8 296 725 $277,718 $63,994
2021 6 224 598 $233,083 $55,970
2020 7 154 395 $159,467 $38,707
Total Patients
937
Total Services
2,293
Medicare Billing
$208,437
Procedure Codes
28

All Medicare Procedures & Services

28 procedure records from CMS Medicare Utilization — Page 2 of 2

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99213 Established patient office or other outpatient visit, typically 15 minutes Office 2020 18 47 $13,019 $3,202 24.6%
99205 New patient office or other outpatient visit, typically 60 minutes Office 2020 15 15 $11,955 $2,928 24.5%
99215 Established patient office or other outpatient, visit typically 40 minutes Office 2020 11 20 $11,140 $2,492 22.4%

About Dr. Uqba Khan, M.D

Dr. Uqba Khan, M.D is a Hematology & Oncology healthcare provider based in Brooklyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/07/2013. The National Provider Identifier (NPI) number assigned to this provider is 1780923920.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Uqba Khan, M.D has received a total of $20,789 in payments from pharmaceutical and medical device companies, with $4,503 received in 2024. These payments were reported across 47 transactions from 19 companies. The most common payment nature is "Consulting Fee" ($19,588).

As a Medicare-enrolled provider, Khan has provided services to 937 Medicare beneficiaries, totaling 2,293 services with total Medicare billing of $208,437. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.

Practice Information

  • Specialty Hematology & Oncology
  • Location Brooklyn, NY
  • Active Since 02/07/2013
  • Last Updated 02/06/2025
  • Taxonomy Code 207RH0003X
  • Entity Type Individual
  • Practice Solo Practitioner
  • NPI Number 1780923920

Products in Payments

  • LUTONIX (Device) $3,991
  • Lutonix DCB (Device) $3,320
  • IMJUDO (Biological) $2,809
  • LUMAKRAS (Drug) $2,744
  • IMFINZI (Biological) $1,763
  • CALQUENCE (Drug) $124.98
  • VELCADE (Drug) $96.25
  • OPDIVO (Biological) $49.62
  • SOMATULINE DEPOT (Drug) $44.62
  • Vitrakvi (Drug) $33.40
  • Venclexta (Drug) $28.05
  • LORBRENA (Drug) $27.05
  • ZYTIGA (Drug) $26.93
  • Imbruvica (Drug) $25.33
  • ZEJULA (Drug) $22.41
  • VYXEOS (Drug) $20.22
  • VERZENIO (Drug) $20.00
  • Pomalyst (Drug) $19.74
  • Stivarga (Drug) $19.50
  • DARZALEX (Biological) $16.79

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Hematology & Oncology Doctors in Brooklyn